Compounds > monomethyl auristatin e
Page last updated: 2024-11-12

monomethyl auristatin e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11542188
CHEMBL ID2103835
SCHEMBL ID5402144
MeSH IDM0479916

Synonyms (39)

Synonym
HY-15162
n-methyl-l-valyl-n-[(3r,4s,5s)-1-{(2s)-2-[(1r,2r)-3-{[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n-methyl-l-valinamide
DASWEROEPLKSEI-UIJRFTGLSA-N
mmae
474645-27-7
monomethyl auristatin e
mmae peptide
mmae, monomethyl auristatin e
l-valinamide, n-methyl-l-valyl-n-((1s,2r)-4-((2s)-2-((1r,2r)-3-(((1r,2s)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1s)-1-methylpropyl)-4-oxobutyl)-n-methyl-
n-methyl-l-valyl-n-((1s,2r)-4-((2s)-2-((1r,2r)-3-(((1r,2s)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1s)-1-methylpropyl)-4-oxobutyl)-n-methyl-l-valinamide
n(sup 2)-(n-methyl-l-valyl)-n(sup 1)-((1s,2r)-4-((2s)-2-((1r,2r)-3-(((1r,2s)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1s)- 1-methylpropyl)-4-oxobutyl)-n(sup 1)-methyl-l-valinamide
v7i58rc5ej ,
unii-v7i58rc5ej
CS-0837
CHEMBL2103835
S7721
sgd-1010
monomethylauristatin e [mi]
BP-22278
AKOS025312191
(2s)-n-[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
SCHEMBL5402144
monomethyl auristatin e (mmae)
4q5 ,
n-methyl-l-valyl-n-[(1s,2r)-4-[(2s)-2-[(1r,2r)-3-[[(1r,2s)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1s)-1-methylpropyl]-4-oxobutyl]-n-methyl-l-valinamide
mfcd22124498
(2s)-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-2-{[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]carbamoyl}-1-methoxy-2-methylethyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethyl-2-[(2s)-3-methyl-2-(methylamino)butanamido]butanamide
(s)-n-((3r,4s,5s)-1-((s)-2-((1r,2r)-3-(((1r,2r)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohe
mmae (monomethyl auristatin e)
Q6901739
(s)-n-((3r,4s,5s)-1-((s)-2-((1r,2r)-3-(((1s,2r)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-n,3-dimethyl-2-((s)-3-methyl-2-(methylamino)butanamido)butanamide
AMY9235
CCG-270400
nsc-832263
nsc832263
FD9056
nsc791792
nsc-791792
DTXSID101028844

Research Excerpts

Overview

Monomethyl auristatin E (MMAE) is an extremely potent peptide drug. It is currently used in the form of antibody drug conjugates (ADCs) for treating different cancers. MMAE is a potent anti-cancer microtubule-targeting agent (MTA)

ExcerptReferenceRelevance
"Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody-drug conjugates (ADC). "( Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
Balthasar, JP; Bordeau, BM; Chen, P; Nguyen, TD; Polli, JR, 2023)		2.35
"Monomethyl auristatin E (MMAE) is a potent anti-cancer microtubule-targeting agent (MTA) used as a payload in three approved MMAE-containing antibody drug conjugates (ADCs) and multiple ADCs in clinical development to treat different types of cancers. "( Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Azarenko, O; Best, RL; Chih, S; Feinstein, SC; Genualdi, C; Jordan, MA; LaPointe, NE; Miller, H; Shen, BQ; Stagg, NJ; Wilson, L, 2021)		2.27
"Monomethyl auristatin E (MMAE) is an extremely potent peptide drug that is currently used in the form of antibody drug conjugates (ADCs) for treating different cancers. "( Cyclic RGD-Peptide-Functionalized Polylipopeptide Micelles for Enhanced Loading and Targeted Delivery of Monomethyl Auristatin E.
Deng, C; Qiu, M; Sun, H; Wang, X; Zhang, J; Zhong, Z, 2018)		2.14

Toxicity

ExcerptReferenceRelevance
" Most common adverse events were infusion-related reaction (22/45; 49%) and fatigue (20/45; 44%)."( A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Ansell, PJ; Barch, D; Calvo, E; Cleary, JM; Gifford, M; Hu, B; Juric, D; Moreno, V; Ocampo, C; Roberts-Rapp, L; Shapiro, GI; Tolcher, AW; Vanderwal, CA; Xiong, H, 2020)		0.76
" The most common adverse events were fatigue, nausea, abdominal pain, constipation, blurred vision, diarrhea, and anemia."( An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Barroilhet, L; Burris, H; Choeurng, V; Commerford, R; Gutierrez, M; Humke, E; Liu, J; Moore, K; Royer-Joo, S; Vaze, A; Wang, JS; Wang, Y, 2021)		0.62
" The highest non-severely toxic dose of RC88-ADC was 5 mg/kg in monkeys after repeated dosing."( Preclinical safety profile of RC88-ADC：a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E.
Jiang, J; Li, S; Tang, N; Wang, L; Xin, W, 2023)		1.13

Pharmacokinetics

ExcerptReferenceRelevance
" The objective of this work was to build a physiologically based pharmacokinetic (PBPK) model to assess MMAE-drug interactions for vc-MMAE ADCs."( Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H, 2015)		0.42
" The model was developed using in silico and in vitro data and in vivo pharmacokinetic data from anti-CD22-vc-MMAE ADC."( Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H, 2015)		0.42
"The pharmacokinetic profile of acMMAE and unconjugated MMAE following administration of anti-CD22-vc-MMAE was well described by simulations using the developed PBPK model."( Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H, 2015)		0.42
" We developed a mechanism-based platform model that can describe and predict the complex pharmacokinetic (PK) behavior of ADCs with protease-cleavable valine-citrulline (VC) linker linked to Monomethylmonomethyl auristatin F/E by incorporating known mechanisms of ADC disposition."( Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Carrasco-Triguero, M; Fielder, P; Gadkar, K; Leipold, DD; Lin, K; Milojic-Blair, M; Ramanujan, S; Rubinfeld, B; Saad, OM; Samineni, D; Sukumaran, S; Wang, B; Xu, K; Zhang, C, 2017)		0.46
" The goal of this analysis was to develop a platform model that simultaneously described antibody-conjugated MMAE (acMMAE) pharmacokinetic (PK) data from eight vc-MMAE ADCs, against different targets and tumor indications; and to assess differences and similarities of model parameters and model predictions, between different compounds."( Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Agarwal, P; Chen, SC; Fine, BM; Gibiansky, L; Girish, S; Jin, JY; Kågedal, M; Koppada, N; Li, C; Lu, D; Saad, O; Samineni, D; Wang, B; Wang, X; Xu, J, 2017)		0.46
" Pharmacokinetic analysis of H-Zt/g4-MMAE was determined using hydrophobic interaction chromatography and a MMAE ADC ELISA kit."( Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Chen, LH; Feng, L; Hu, CY; Jun, ES; Kim, SC; Suthe, SR; Tong, XM; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP, 2019)		0.51
"H-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities."( Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Chen, LH; Feng, L; Hu, CY; Jun, ES; Kim, SC; Suthe, SR; Tong, XM; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP, 2019)		0.51
" Population pharmacokinetic (PK) and exposure-response models were developed to quantify sources of PK variability and relationships between exposure and safety/efficacy end points in ECHELON-1."( Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Collins, GP; Endres, CJ; Gomez-Navarro, J; Mould, DR; Song, G; Suri, A; Venkatakrishnan, K, 2019)		0.51
" Pharmacokinetic analysis of losatuxizumab vedotin showed exposures appeared to be approximately dose-proportional."( A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Ansell, PJ; Barch, D; Calvo, E; Cleary, JM; Gifford, M; Hu, B; Juric, D; Moreno, V; Ocampo, C; Roberts-Rapp, L; Shapiro, GI; Tolcher, AW; Vanderwal, CA; Xiong, H, 2020)		0.76
" For the first time, we developed a physiologically based pharmacokinetic (PBPK) model-based approach to assess CYP3A-mediated drug-drug interaction (DDI) risk for polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC)."( Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Chen, Y; Ding, H; Girish, S; Jin, J; Li, C; Lu, D; Ma, F; Mao, J; Miles, D; Samineni, D; Shi, R; Wright, M, 2020)		0.74
" The exposure of acMMAE was dose proportional, with a half-life of ~6 days."( An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Barroilhet, L; Burris, H; Choeurng, V; Commerford, R; Gutierrez, M; Humke, E; Liu, J; Moore, K; Royer-Joo, S; Vaze, A; Wang, JS; Wang, Y, 2021)		0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE."( CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Alley, SC; Chen, R; Cooper, M; Gopal, AK; Goy, A; Grove, LE; Han, TH; Lynch, CM; Matous, JV; O'Connor, OA; Ramchandren, R, 2013)		0.39
" Therefore, evaluating the drug-drug interaction (DDI) potential associated with MMAE is important in the clinical development of ADCs."( Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H, 2015)		0.42
" For the first time, we developed a physiologically based pharmacokinetic (PBPK) model-based approach to assess CYP3A-mediated drug-drug interaction (DDI) risk for polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC)."( Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Chen, Y; Ding, H; Girish, S; Jin, J; Li, C; Lu, D; Ma, F; Mao, J; Miles, D; Samineni, D; Shi, R; Wright, M, 2020)		0.74

Dosage Studied

ExcerptRelevanceReference
" Glembatumumab vedotin had a relatively short t(1/2) , prompting the evaluation of more frequent dosing schedules."( Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Junutula, JR; Naumovski, L, 2010)		0.58
" Pharmacokinetic data showed approximately dose proportional systemic exposure and a mean plasma half-life of around 4 days, supporting the dosing schedule."( Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna, K; Cruz, C; Faris, JE; Fasanmade, AA; Jung, J; Kalebic, T; Messersmith, W; Rodon, J; Ryan, DP; Wyant, T, 2016)		0.43
" Time-dependence of clearance had no effect beyond the first dosing cycle."( Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Agarwal, P; Chen, SC; Fine, BM; Gibiansky, L; Girish, S; Jin, JY; Kågedal, M; Koppada, N; Li, C; Lu, D; Saad, O; Samineni, D; Wang, B; Wang, X; Xu, J, 2017)		0.46
" In addition, depatux-m dosing has been limited by corneal side effects common to MMAF conjugates."( Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Benatuil, L; Boghaert, ER; Buchanan, FG; Cao, D; DeVries, PJ; Durbin, KR; Falls, HD; Gan, HK; Hsieh, CM; Loberg, LI; Meulbroek, JA; Mitten, MJ; Mudd, SR; Panchal, SC; Phillips, AC; Ralston, SL; Reilly, EB; Reuter, DR; Scott, AM; Vaidya, KS; Voorbach, MJ, 2018)		0.48
" This model can be used to inform clinical strategies such as adaptations to dosing regimen and/or treatment duration as well as inform clinical eligibility to reduce the incidence of grade ≥ 2 PN."( Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates.
Fine, BM; Gillespie, WR; Girish, S; Jin, JY; Kågedal, M; Li, C; Lu, D; Samineni, D, 2019)		0.51
" Here, we describe the biodistribution and toxicology assessments in Sprague-Dawley rats after intravenous dosing with the aim of elucidating the relationships between these biological outcomes and the underlying physicochemical properties of non-targeted ADCs."( Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.
Burke, PJ; Cochran, JH; Lyon, RP; Pittman, PG; Simmons, JK, 2020)		0.56
"3 mg/kg over 3 h per 21-day cycle, with alternate dosing schedules utilized (2 weeks on/1 week off or weekly) to mitigate infusion reactions."( A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Ansell, PJ; Barch, D; Calvo, E; Cleary, JM; Gifford, M; Hu, B; Juric, D; Moreno, V; Ocampo, C; Roberts-Rapp, L; Shapiro, GI; Tolcher, AW; Vanderwal, CA; Xiong, H, 2020)		0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID768618Antiproliferative activity against human A549 cells after 4 days by XTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
AID1854921Antitumor activity against KK-LC-1-positive human MKN-45 cells xenografted in male BALB/c nude mouse assessed as tumor volume2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1508474Growth inhibition of human SF268 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID768605Antitumor activity against mouse LLC cells allografted in C57/BL6 mouse assessed as reduction in tumor weight at 0.1 mg/kg, iv administered on day 7, 11 and 14 post transplantation measured on day 20 relative to control2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
AID1854901Induction of mitotic arrest in KK-LC-1-positive human NUGC-4 cells xenografted in nude mouse assessed as number of pHH3-positive nuclei in tumor at 4 nmol, iv administered as single dose and measured after 24 hrs by pHH3 immunohistochemical staining metho2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1508473Growth inhibition of human MCF7 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID768606Cytotoxicity against human non-small cell lung cancer cells at 0.5 to 1 nM after 4 days by XTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
AID1896535Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1508477Growth inhibition of human DU145 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID1896537Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1171856Apparent intrinsic clearance in human liver hepatocytes at 1 uM2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
AID1501974Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1478513Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1501972Growth inhibition of human MCF7 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1508476Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID1813534Acute toxicity in iv dosed Wistar male rat assessed as maximum non-lethal dose2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1501973Growth inhibition of human SF268 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1896534Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1813535Acute toxicity in Wistar rat assessed as decrease in motor activity2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1501971Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1508472Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID1478512Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1501975Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1813522Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1389361Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
AID768617Antiproliferative activity against human KB cells after 4 days by XTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
AID1501976Growth inhibition of human DU145 cells after 48 hrs by SRB assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates.
AID1389363Permeability of the compound at 200 umol/L after 5 hrs by PAMPA2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
AID1854879Cytotoxicity against KK-LC-1-negative human HGC-27 cells incubated for 72 hrs by CCK-8 assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1478510Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1171855Apparent intrinsic clearance in human liver microsomes at 1 uM2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
AID1638694Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.
AID1171852Cytotoxicity against human BT474 cells assessed as cell viability incubated fore 4 days by MTS assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
AID1478511Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1478508Growth inhibition of human BxPC3 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1389360Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
AID1895044Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition in cell growth2021Journal of natural products, 05-28, Volume: 84, Issue:5
Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors.
AID768616Antiproliferative activity against human MDA-MB-231 cells after 4 days by XTT assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
AID1478509Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay2017Journal of natural products, 03-24, Volume: 80, Issue:3
Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors.
AID1896519Toxicity in CD-1 mouse assessed as body weight loss at 0.4 mg/kg,ip administrated upto 20 days for every 5 days2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1813524Induction of intracellular reactive oxygen species production in human 22Rv1 cells incubated for 1 hr measured at CC50 concentration by amperometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1502929Antiproliferative activity against human U87 cells after 72 hrs by MTS assay2017Journal of natural products, 10-27, Volume: 80, Issue:10
Cytotoxic Prenylated Stilbenes Isolated from Macaranga tanarius.
AID1813538Acute toxicity in Wistar rat assessed as decrease in porphyrin release from nose mucous membrane at 30 mg/kg, iv2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1896538Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1171853Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
AID1854878Cytotoxicity against KK-LC-1-positive human MKN-45 cells incubated for 72 hrs by CCK-8 assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1502930Antiproliferative activity against human A549 cells after 72 hrs by MTS assay2017Journal of natural products, 10-27, Volume: 80, Issue:10
Cytotoxic Prenylated Stilbenes Isolated from Macaranga tanarius.
AID1896533Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1813533Acute toxicity in iv dosed ICR male mouse assessed as maximum non-lethal dose2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1813523Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1813537Acute toxicity in Wistar rat assessed as decrease in porphyrin release from eye mucous membrane at 30 mg/kg, iv2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1813525Induction of intracellular reactive oxygen species production in human PC-3 cells incubated for 1 hr measured at CC50 concentration by amperometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1895048Cytotoxicity against human MES-SA cells assessed as inhibition in cell growth2021Journal of natural products, 05-28, Volume: 84, Issue:5
Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors.
AID1895049Cytotoxicity against HEK293T cells assessed as inhibition in cell growth2021Journal of natural products, 05-28, Volume: 84, Issue:5
Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors.
AID1813536Acute toxicity in Wistar rat assessed as damage in liver at 30 mg/kg, iv2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1508475Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay2018Journal of natural products, 03-23, Volume: 81, Issue:3
Antineoplastic Agents. 605. Isoquinstatins.
AID1854877Cytotoxicity against KK-LC-1-positive human NUGC-4 cells incubated for 72 hrs by CCK-8 assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1854918Antitumor activity against KK-LC-1-positive human MKN-45 cells xenografted in male BALB/c nude mouse assessed as reduction in tumor growth2022European journal of medicinal chemistry, Nov-05, Volume: 241An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.
AID1171854Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
AID1389362Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
AID1896536Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (211)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (6.16)29.6817
2010's136 (64.45)24.3611
2020's62 (29.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.15 (24.57)
Research Supply Index5.42 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index85.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (4.63%)5.53%
Reviews9 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other197 (91.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.2510amino-acid anion
coumarin
2H-chromen-2-one: coumarin derivative		2.2510coumarinsfluorescent dye;
human metabolite;
plant metabolite
glycine
[no description available]		2.3110alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		7.2110alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.5720monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.1710branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.3110
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.1710nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		6.3642dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		6.3642imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
sulfaphenazole
Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.		2.3110primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		2.111011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		7.1510alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.0310L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.2510aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.0310amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
bromoacetate
[no description available]		2.2510carboxylic acid;
organohalogen compound
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		8.6480L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.1110erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
divinyl sulfone
divinyl sulfone: cross-linking reagent for agarose gels. divinyl sulfone : A sulfone compound having two S-vinyl substituents.		2.2510sulfonecross-linking reagent
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.1510pyrrole;
secondary amine
indolebutyric acid
indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.		2.1310indol-3-yl carboxylic acidauxin;
plant hormone;
plant metabolite
1,2,4,5-tetrazine
[no description available]		2.2510tetrazine
citrulline
citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.		3.5270amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite
maleimide
[no description available]		2.8930dicarboximide;
maleimides		EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
succinimide
succinimide: RN given refers to parent cpd. succinimide : A dicarboximide that is pyrrolidine which is substituted by oxo groups at positions 2 and 5.		2.2510dicarboximide;
pyrrolidinone
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		2.3110extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
triethylsilane
[no description available]		2.2510organosilicon compoundreducing agent
n-phenylmaleimide
N-phenylmaleimide: structure in Merck Index, 9th ed, #7104		2.1110
deoxycytidine
[no description available]		2.4920pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
durapatite
Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).		2.1310
tranylcypromine
Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.		2.31102-phenylcyclopropan-1-amine
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		7.4110copper group element atom;
elemental gold
zirconium
Zirconium: A rather rare metallic element with atomic number 40, atomic weight 91.224, and symbol Zr.		2.1310titanium group element atom
fluorides
[no description available]		2.3110halide anion;
monoatomic fluorine
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.2510benzenes;
phenyl acetates
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		2.8130pseudohalide anionmitochondrial respiratory-chain inhibitor
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		3.4110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		2.1110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.4920organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		2.1710carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
rhodamine 110
rhodamine 110: RN given refers to chloride		2.1510
haba
2-(4-hydroxyphenylazo)benzoic acid : An azo compound that is azobenzene in which one phenyl group is substituted at position 4 by a hydroxy group, while the other phenyl group is substituted at position 2 by a carboxy group. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry.		2.1310
n-formylglycine
glycal : A cyclic enol ether derivative of a sugar having a double bond specifically between carbon atoms 1 and 2 in the ring.		2.3110N-acylglycine;
N-formyl amino acid
6-carboxyfluorescein
6-carboxyfluorescein: originally sold as 6-carboxyfluorescein, but commercial product is a mixture of two isomers; correct name is 5(6)-carboxyfluorescein		2.3110monocarboxylic acid
arginyl-glycyl-aspartic acid
arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system		2.7220oligopeptide
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.		2.0810azamacrocyclechelator;
copper chelator
4-azidobenzylcarazolol
[no description available]		2.1310
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.9830secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.5320biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.3110cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		2.3110cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
vedelianin
vedelianin: Cytotoxic; from Macaranga tanarius; structure in first source. vedelianin : A stilbenoid derivative isolated from Macaranga alnifolia and Macaranga alnifolia and has been shown to exhibit cytotoxic activity.		2.1510cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		antineoplastic agent;
plant metabolite
cotinine
Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.		2.2510N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
montelukast
montelukast: a leukotriene D4 receptor antagonist		2.3110aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		2.830alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		8.4770cysteiniumfundamental metabolite
phytochlorin
phytochlorin: RN given refers to (2S-trans)-isomer; structure given in the first source		2.2110
1-palmitoyl-2-oleoylphosphatidylcholine
1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer		2.1110
soblidotin
soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R*(R*),2S*),2R*(1S*,2S*)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.		2.0310tetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
dolastatin 10
dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.		2.57201,3-thiazoles;
tetrapeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
cabazitaxel
cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.		2.2110tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
fr 901464
[no description available]		3.4110acetate ester;
cyclic hemiketal;
monocarboxylic acid amide;
pyrans;
spiro-epoxide		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
spliceostatin a
spliceostatin A: antiangiogenic agent that blocks expression of VEGF; structure in first source		3.4110
tafamidis
tafamidis: may be effective in treating transthyretin amyloid polyneuropathy. tafamidis : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis.		2.41101,3-benzoxazoles;
dichlorobenzene;
monocarboxylic acid		central nervous system drug
carfilzomib
[no description available]		2.2110epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
meayamycin
meayamycin: inhibits pre-mRNA splicing; has antineoplastic activity; structure in first source		3.4110
schweinfurthin g
schweinfurthin G: structure in first source. schweinfurthin G : A stilbenoid that is the 3-deoxy derivative of vedelianin. Isolated from Macaranga alnifolia, it exhibits cytotoxic activity.		2.1510cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		antineoplastic agent;
metabolite
gala peptide
GALA peptide: synthetic 30 amino acid peptide; its association with membrane vesicles has been studied; amino acid sequence given in first source		2.3110
prosomatostatin
[no description available]		2.2110heterodetic cyclic peptide;
peptide hormone		fungal metabolite;
mouse metabolite;
rat metabolite
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.11101,2-diacyl-sn-glycero-3-phosphocholine
schweinfurthin f
schweinfurthin F: structure in first source. schweinfurthin F : A stilbenoid isolated from Macaranga alnifolia and has been shown to exhibit cytotoxic activity.		2.1510cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		metabolite
alpha-amanitin
Alpha-Amanitin: A cyclic octapeptide with a thioether bridge between the cystine and tryptophan. It inhibits RNA POLYMERASE II. Poisoning may require LIVER TRANSPLANTATION.. alpha-amanitin : A heterodetic cyclic peptide consisting of eight amino acid residues and containing a thioether bridge between a cysteine and a tryptophan residue. It is found in a number of poisonous mushrooms, including Amanita phalloides (the death cap), Galerina marginata, and and Conocybe filaris.		2.9430
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.2510benzenes;
hydroxycoumarin;
methyl ketone
idarucizumab
[no description available]		2.4110
thailanstatin a
[no description available]		3.4110C-glycosyl compound
thailanstatin b
[no description available]		3.4110
maytansinol
[no description available]		2.1110
monomethylauristatin f
monomethylauristatin F: structure in first source		3.5370
1,2-dipalmitoyl-sn-glycero-3-phosphothioethanol
[no description available]		2.3110
thromboplastin
Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.		2.8130
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		2.1110folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		6.3642cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.0410dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.0810
Benign Neoplasms
[description not available]		09.08272
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		09.08272
Cancer of Prostate
[description not available]		04.8561
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		04.8561
Cancer of Lung
[description not available]		03.5570
Cancer of Stomach
[description not available]		06.5451
Lung Neoplasms
Tumors or cancer of the LUNG.		03.5570
Stomach Neoplasms
Tumors or cancer of the STOMACH.		06.5451
Cancer of Skin
[description not available]		02.520
Merkel Cell Cancer
[description not available]		02.4110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.520
Carcinoma, Merkel Cell
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)		02.4110
Breast Cancer
[description not available]		04.89110
Breast Neoplasms
Tumors or cancer of the human BREAST.		04.89110
Epithelial Ovarian Cancer
[description not available]		03.711
Cancer of Ovary
[description not available]		05.21101
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		03.711
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		05.21101
Cancer of Cervix
[description not available]		03.2310
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		03.2310
Malignant Melanoma
[description not available]		03.5780
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		03.5780
Uveal Neoplasms
Tumors or cancer of the UVEA.		02.5320
Cancer of Pancreas
[description not available]		04.62200
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		04.62200
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		05.03130
Astrocytoma, Grade IV
[description not available]		03.1340
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		08.1340
Cancer of Colon
[description not available]		02.8930
Colonic Neoplasms
Tumors or cancer of the COLON.		02.8930
Peripheral Nerve Diseases
[description not available]		05.6351
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		05.6351
Bladder Cancer
[description not available]		02.610
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.610
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		03.6420
Metastase
[description not available]		06.2941
Cancer of the Urinary Tract
[description not available]		03.1210
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		06.2941
Neuroendocrine Tumors
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.		07.6620
Innate Inflammatory Response
[description not available]		02.6920
Experimental Mammary Neoplasms
[description not available]		02.6620
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.6920
Infusion Site Adverse Event
[description not available]		03.6411
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4820
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.2510
Osteogenic Sarcoma
[description not available]		02.3110
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.3110
Carcinoma, Non-Small Cell Lung
[description not available]		02.8730
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.8730
Experimental Neoplasms
[description not available]		02.8330
Diffuse Large B-Cell Lymphoma
[description not available]		02.4820
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		02.4820
Benign Neoplasms, Brain
[description not available]		02.1510
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.1510
Hematologic Malignancies
[description not available]		07.9155
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		07.9155
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		04.8671
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		04.8671
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.1510
Cancer, Embryonal
[description not available]		02.1710
Neoplasms, Germ Cell and Embryonal
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.		02.1710
Colorectal Cancer
[description not available]		02.5420
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.5420
Carcinoma, Small Cell Lung
[description not available]		02.1710
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		02.1710
Cancer of Kidney
[description not available]		03.0240
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		03.0240
Carcinoma, Anaplastic
[description not available]		02.1710
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.1710
Peritoneal Carcinomatosis
[description not available]		02.1710
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		02.1710
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		03.1210
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.8330
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.8330
Cells, Neoplasm Circulating
[description not available]		03.5911
Adverse Drug Event
[description not available]		04.5111
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		04.5111
Carcinoma, Ductal, Pancreatic
[description not available]		02.6120
Carcinoma, Pancreatic Ductal
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.		02.6120
Granuloma, Hodgkin
[description not available]		06.2371
Chemotherapy-Induced Febrile Neutropenia
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.		03.5911
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		06.2371
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		03.5911
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.2110
B-Cell Lymphoma
[description not available]		02.9940
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.9940
Recrudescence
[description not available]		03.4220
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		07.110
Complication, Postoperative
[description not available]		02.1110
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		02.1110
Anaplastic Large-Cell Lymphoma
[description not available]		02.7630
Lymphoma, Large-Cell, Anaplastic
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called hallmark cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.		02.7630
Granulocytic Leukemia
[description not available]		02.1110
T-Cell Lymphoma
[description not available]		02.1110
Acute Disease
Disease having a short and relatively severe course.		02.1110
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		02.1110
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		02.1110
Lymphoma, T Cell, Peripheral
[description not available]		02.1110
Local Neoplasm Recurrence
[description not available]		02.1110
Lymphoma, T-Cell, Peripheral
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.		02.1110
Germinoblastoma
[description not available]		02.1310
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.1310
Adenocarcinoma, Basal Cell
[description not available]		03.5111
Cancer of Gastrointestinal Tract
[description not available]		03.5111
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		03.5111
Bone Cancer
[description not available]		02.1310
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.1310
Leukemia, Pre-B-Cell
[description not available]		02.1510
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.		02.1510
Adenocarcinoma Of Kidney
[description not available]		02.4720
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		02.4720
Weight Reduction
[description not available]		02.0510
Weight Loss
Decrease in existing BODY WEIGHT.		02.0510
B16 Melanoma
[description not available]		02.4520